People: Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

23.55USD
20 Oct 2014
Price Change (% chg)

$0.57 (+2.48%)
Prev Close
$22.98
Open
$22.89
Day's High
$23.56
Day's Low
$22.84
Volume
64,375
Avg. Vol
72,693
52-wk High
$30.77
52-wk Low
$20.10

Search Stocks

Summary

Name Age Since Current Position

Michael Minogue

47 2005 Chairman of the Board, President, Chief Executive Officer

Robert Bowen

64 2008 Chief Financial Officer, Vice President, Treasurer

David Weber

52 2007 Chief Operating Officer

William Bolt

62 2011 Senior Vice President - Global Product Operations

Andrew Greenfield

41 2014 Vice President, General Manager - Global Marketing

Michael Howley

50 2009 Vice President, General Manager - Global Sales and Marketing

Dorothy Puhy

62 2005 Lead Independent Director

Eric Rose

63 2014 Director

W. Gerald Austen

84 1985 Independent Director

Louis Lataif

75 2005 Independent Director

Martin Sutter

59 2008 Independent Director

Henri Termeer

68 1987 Independent Director

Paul Thomas

58 2011 Independent Director

Ingrid Goldberg

2014 Director - Investor Relations

Biographies

Name Description

Michael Minogue

Mr. Michael R. Minogue is Chairman of the Board, President, Chief Executive Officer of Abiomed Inc. He has served as Chief Executive Officer, President and a director since April 2004. In June 2005 he was appointed Chairman of Board of Directors. Prior to joining the company, Mr. Minogue had a twelve-year career at General Electric, or GE. Most recently, Mr. Minogue was Vice President and General Manager of Americas Sales and Marketing for GE Medical Systems Information Technology. From 1997 to 2004 Mr. Minogue held various positions at GE including General Manager for the Global Positron Emission Technology Business, General Manager, Americas Cardiology & IT Sales and General Manager, Global Installed Base. Prior to joining GE, Mr. Minogue served on active duty for four years as an infantry officer in the U.S. Army and received multiple awards. Mr. Minogue received his Bachelor of Science in Engineering Management from the United States Military Academy at West Point and his Master of Business Administration from the University of Chicago. Mr. Minogue currently serves on the Board of Directors of the Advanced Medical Technology Association, or AdvaMed. He was formerly designee on the Board of Directors of World Heart Corporation, and was formerly on the Board of Directors of LifeCell Corporation, which was acquired by Kinetic Concepts, Inc. in May 2008.

Robert Bowen

Mr. Robert L. Bowen is Chief Financial Officer, Vice President, Treasurer of Abiomed Inc., since December, 2008. From December 2005 until November 2008, Mr. Bowen was Vice President and Chief Financial Officer of GSI Group, a supplier of lasers, laser systems and precision motion technologies. GSI Group filed for chapter 11 bankruptcy protection in 2009 and emerged from bankruptcy protection in 2010. From November 2003 to December 2005, Mr. Bowen was an independent consultant and co-founder of Graystone Capital Partners LLC. From December 2000 to October 2003, Mr. Bowen was Vice President and Chief Financial Officer of Cytyc Corporation, a maker of cancer diagnostic and other medical devices, and prior to that, Chief Financial Officer for the European Region for Case Corporation. Mr. Bowen also held a variety of financial positions at General Electric over a 20 year span. Mr. Bowen has a Bachelor of Business Administration from Ohio University and a Master of Business Administration from New York University’s Stern School.

David Weber

Dr. David M. Weber is Chief Operating Officer of Abiomed Inc., since April, 2007. Prior to joining the company, Dr. Weber served as General Manager, Aviation Business at GE Security—Homeland Protection from April 2005 until April 2007 where he led GE Security’s Aviation and Transportation Business and was responsible for product development, marketing and sales. From June 2004 until April 2005, he served as General Manager, MRI Marketing at GE Healthcare where he was responsible for strategic product planning, go-to-market and product launch activities including developing product roadmaps and introducing new product technologies to the market, and from March 2001 until June 2004, he served as Manager, Global High Field MRI Business, GE Medical Systems where he was responsible for new product planning and development. Dr. Weber has a Bachelor of Science in physics from Denison University, a Bachelor of Science in Nuclear Engineering from Columbia University, a Master of Science in Medical Physics from the University of Wisconsin—Madison, and a Doctor of Philosophy in Medical Physics from the University of Wisconsin—Madison.

William Bolt

Mr. William J. Bolt is Senior Vice President - Global Product Operations of Abiomed Inc. He is currently responsible for all product development, management, engineering, regulatory and quality functions. From 2006 to 2009 he was responsible, at different times, for quality regulatory and engineering functions. From 2003 to 2006 he was responsible for quality and service functions. He was responsible for all product development and the AbioCor program from 2000-2003, and for BVS and AB5000 development from 1999-2003. From 1994 to 1999, he was President of former dental subsidiary, ABIODENT. From 1982 to 1994, he served in various roles, from Vice President of Engineering to Vice President of Operations. Mr. Bolt received both his Bachelor of Science in Electrical Engineering and Master of Business Administration from Northeastern University.

Andrew Greenfield

Mr. Andrew J. Greenfield is Vice President, General Manager - Global Marketing of Abiomed Inc., serves as our Vice President and General Manager of Global Marketing. Prior to joining us, Mr. Greenfield held multiple positions at GE Healthcare since October 1999, including consulting with large U.S. health systems in the Enterprise Client Group from November 2003 to January 2005, Six Sigma Master Black Belt from January 2002 to November 2003, and Finance Manager from October 1999 to January 2002. Prior to GE Healthcare, he held multiple positions in marketing and sales management at the Boeing Company, including Project Manager and European Country Manager. He received his Bachelor of Science in Finance from the University of Illinois and his Master of Business Administration from St. Louis University.

Michael Howley

Mr. Michael G. Howley is Vice President, General Manager - Global Sales and Marketing of Abiomed Inc., since March, 2009. Prior to joining the company, Mr. Howley spent 20 years at GE Healthcare. From February 2006 to February 2009, he was General Manager at GE Healthcare, overseeing the Americas X-ray and Interventional Radiology division. From April 2004 to February 2006, Mr. Howley held the General Manager position for the Clinical Information Systems at GE. From October 2002 to April 2004, he was the Americas Sales Manager of Functional and Molecular Imaging. Prior to this role, Mr. Howley held several other national and regional sales positions at GE, beginning his tenure with the company in 1989. Mr. Howley has a Bachelor of Science in Business Administration and Marketing from Auburn University.

Dorothy Puhy

Ms. Dorothy E. Puhy is Lead Independent Director of Abiomed Inc. Ms. Puhy has served as a director since August 2003 and as Lead Director since October 2005. Ms. Puhy has served as Executive Vice President and Chief Operating Officer for the Dana-Farber Cancer Institute since 2012. Ms. Puhy previously served as the Chief Financial Officer of Dana-Farber from 1994 to 2012 and as its Assistant Treasurer from 1995 to 2012. From 1985 to 1994 Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994. Ms. Puhy is also a director of Eaton Vance Corp. Ms. Puhy received her Bachelor of Arts from the University of Pennsylvania and her Master of Business Administration from the Wharton School of Business at the University of Pennsylvania.

Eric Rose

Dr. Eric A. Rose, M.D., Class II., is a Director of Abiomed Inc.. Dr. Rose has been serving since March 2007 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer of Siga Technologies, Inc., a developer of anti-viral drugs directed at potential agents of bioterror. From 1994 to 2007, he was Surgeon in Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose has helped grow Columbia’s Department of Surgery over the past 25 years while investigating, managing and developing complex medical technologies such as technologies for heart transplantation and new approaches to Alzheimer’s disease and bioterrorism. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received both his undergraduate and medical degrees from Columbia University.

W. Gerald Austen

Dr. W. Gerald Austen, M.D., is an Independent Director of Abiomed Inc., since May 1985. Dr. Austen has served as the chair of the Massachusetts General Hospital Chief’s Counsel since 1992. From 1974 to 2011, he was the Edward D. Churchill Professor of Surgery at Harvard Medical School and at Massachusetts General Hospital. In 2011, he was named the Edward D. Churchill Distinguished Professor of Surgery at Harvard Medical School and at Massachusetts General Hospital. From 1969 to 1997, Dr. Austen was chief of the surgical services at Massachusetts General Hospital. Dr. Austen is the former President of the American College of Surgeons, the American Association for Thoracic Surgery, the American Surgical Association and the Massachusetts and American Heart Associations. Dr. Austen is a member emeritus of the Institute of Medicine of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, a life member emeritus of the corporation of the Massachusetts Institute of Technology and Chairman emeritus of the board of trustees of the John S. and James L. Knight Foundation. Dr. Austen received his Bachelor of Science from MIT and his Doctor of Medicine from Harvard Medical School.

Louis Lataif

Mr. Louis E. Lataif is an Independent Director of Abiomed Inc., since September 2005. From 1991 through 2010, Mr. Lataif served as Dean of the Boston University School of Management. Prior to joining Boston University in 1991, Mr. Lataif worked with Ford Motor Company for more than 27 years and retired as a corporate officer. He also served as President of Ford of Europe, with global experience. He earned a Bachelor of Science from Boston University and his Master of Business Administration from Harvard University. In addition, he holds three honorary doctoral degrees. Mr. Lataif is a director of Group I Automotive, Inc. He is also a trustee of the Iacocca Foundation, a board member of Interaudi Bank and a member of the Cannon Design International Advisory Board.

Martin Sutter

Mr. Martin P. Sutter is an Independent Director of Abiomed Inc., since May 2008. Since 1994, Mr. Sutter has been a managing director of Essex Woodlands Health Ventures, a healthcare focused growth equity firm he co-founded. Mr. Sutter has more than 30 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter currently serves on the Board of Directors of QSpex Technologies, Inc., a manufacturer of prescription spectacle lenses. Mr. Sutter holds a Bachelors of Science from Louisiana State University and a Masters of Business Administration from the University of Houston.

Henri Termeer

Mr. Henri A. Termeer is an Independent Director of Abiomed Inc., since May 1987. Prior to Genzyme Corporation’s acquisition in April 2011 by Sanofi, Mr. Termeer had been the President, and a director of Genzyme Corporation since 1983, its Chief Executive Officer since 1985 and its Chairman since 1988. Mr. Termeer is a member of the Board of Directors of the Massachusetts Institute of Technology, Massachusetts General Hospital and Partners HealthCare. Mr. Termeer is a member of the Board of Fellows of Harvard Medical School. He is also the Chairman of the Board of Aveo Pharmaceuticals and member of the Board of Directors of Verastem, Inc. Mr. Termeer served as the Deputy Chairman of the Federal Reserve Bank of Boston from 2007 to 2009 and as its Chairman from 2010 through the end of 2011. Mr. Termeer studied economics at the Economische Hogeschool at Erasmus University in The Netherlands and received his Master of Business Administration from the Darden School of Business at the University of Virginia.

Paul Thomas

Mr. Paul G. Thomas is an Independent Director of Abiomed Inc., since May 2011. Mr. Thomas has been the Chief Executive Officer of Roka Bioscience, Inc. since September 2009. Previously he served as Chairman, Chief Executive Officer, and President of LifeCell Corporation from October 1998 until August 2008. Prior to joining LifeCell, Mr. Thomas held various senior positions during a 15-year tenure with the Pharmaceutical Products division of Ohmeda Inc. Mr. Thomas currently serves on the Board of Directors of Aegerion Pharmaceuticals, Inc. and was a member of the Board of Directors of Orthovita, Inc. until its sale in June 2011 to Stryker Corporation. Mr. Thomas received his Master of Business Administration from Columbia University, and completed his postgraduate studies in chemistry at the University of Georgia. He received his Bachelor of Science in Chemistry from St. Michael’s College.

Ingrid Goldberg

Ms. Ingrid Goldberg has been appointed as Director - Investor Relations of Abiomed, Inc. Prior to joining Abiomed, Ms. Goldberg was a Vice President at Bank of America Merrill Lynch. During her 9 year tenure at the bank, Ms. Goldberg held positions of increasing responsibility on the Capital Markets, Sales and Trading teams where she managed a ~$200mm portfolio. Ms. Goldberg received a bachelor's degree from Princeton University where she majored in Political Science and played on the two-time National Championship and four-time Ivy League Title winning D1 Women's Lacrosse Team.

Basic Compensation

Name Fiscal Year Total

Michael Minogue

4,606,670

Robert Bowen

1,173,660

David Weber

1,492,500

William Bolt

1,183,400

Andrew Greenfield

536,074

Michael Howley

1,331,210

Dorothy Puhy

--

Eric Rose

--

W. Gerald Austen

--

Louis Lataif

--

Martin Sutter

--

Henri Termeer

--

Paul Thomas

--

Ingrid Goldberg

--
As Of 30 Mar 2014

Options Compensation

Name Options Value

Michael Minogue

536,800 2,815,549

Robert Bowen

82,500 2,182,500

David Weber

6,500 162,500

William Bolt

262,700 2,065,657

Andrew Greenfield

0 0

Michael Howley

55,000 1,482,560

Dorothy Puhy

0 0

Eric Rose

0 0

W. Gerald Austen

0 0

Louis Lataif

0 0

Martin Sutter

0 0

Henri Termeer

0 0

Paul Thomas

0 0

Ingrid Goldberg

0 0
Search Stocks